01—Abstract
Summary
Summary of the 8-K filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated (Nasdaq: INSM) filed an 8-K on October 31, 2024 reporting two financing actions and its third-quarter 2024 results.
On October 31, 2024, the company entered into an Amended and Restated Loan Agreement with BioPharma Credit PLC as Collateral Agent and funds managed by Pharmakon Advisors, LP. The agreement adds a new $150 milliona senior secured Tranche B Term Loan, continues the $350 million Tranche A Term Loan (plus $46,769,917 of accrued and capitalized paid-in-kind interest), carries a fixed rate of 9.60% per annum, and extends maturity to September 30, 2029, subject to acceleration to February 1, 2028 on certain prespecified events. The company also signed a First Amendment to its Revenue Interest Purchase Agreement with OrbiMed Royalty & Credit Opportunities IV, LP, which amends restrictions on incurring indebtedness.
For the third quarter of 2024, total revenue was $93.4 millionb, up 18% year over year from $79.1 million, with ARIKAYCE net sales of $66.9 million in the U.S., $21.0 million in Japan, and $5.6 million in Europe and rest of world. Net loss widened to $220.5 million, or $1.27 per share, from $158.9 million, or $1.11 per share, in the prior-year quarter. R&D expense rose to $150.8 million and SG&A to $118.9 million, reflecting manufacturing, compensation, and launch-readiness spending for brensocatib.
Cash, cash equivalents, and marketable securities totaled $1,467.9 millionc at September 30, 2024. The company reiterated full-year 2024 global ARIKAYCE revenue guidance of $340 million to $360 million and said it remains on track to submit the brensocatib NDA for bronchiectasis in the fourth quarter of 2024, with a potential U.S. launch in mid-2025 if priority review is granted.
02—Key points
Key Highlights
- Q3 2024 total revenue of $93.4 million, up 18% year over year from $79.1 million
- Net loss of $220.5 million, or $1.27 per share, versus $158.9 million, or $1.11 per share, in Q3 2023
- New $150 million Tranche B Term Loan added under the amended Pharmakon loan, with proceeds expected in Q4 2024
- Term loans bear a fixed rate of 9.60% per annum with maturity extended to September 30, 2029 (acceleration to February 1, 2028 possible on certain events)
- Cash, cash equivalents, and marketable securities of $1,467.9 million as of September 30, 2024
- Full-year 2024 global ARIKAYCE revenue guidance reiterated at $340 million to $360 million
- Brensocatib NDA submission for bronchiectasis remains on track for Q4 2024, with a potential U.S. launch in mid-2025
03—Questions
Frequently Asked Questions
What new financing did Insmed enter into?
On October 31, 2024, Insmed entered into an Amended and Restated Loan Agreement with BioPharma Credit PLC as Collateral Agent and funds managed by Pharmakon Advisors, LP. It adds a $150 million senior secured Tranche B Term Loan to the existing $350 million Tranche A Term Loan, and the loans are secured by substantially all company assets. The company also amended its Revenue Interest Purchase Agreement with OrbiMed to change restrictions on incurring indebtedness.
What are the key terms of the amended term loans?
The Term Loans bear a fixed rate of 9.60% per annum and mature September 30, 2029, subject to acceleration to February 1, 2028 on certain prespecified events. Insmed agreed to pay Pharmakon a fee of 2.00% of the Tranche B Term Loan at closing and an exit fee of 2.00% of the amount of each prepayment or repayment. Repayment in eight equal quarterly installments begins January 3, 2028.
How did Insmed perform financially in the third quarter of 2024?
Total revenue was $93.4 million, up 18% from $79.1 million a year earlier. R&D expenses rose to $150.8 million from $109.1 million and SG&A rose to $118.9 million from $90.6 million, largely due to manufacturing, compensation, and brensocatib launch-readiness costs. The net loss was $220.5 million, or $1.27 per share, compared with $158.9 million, or $1.11 per share, a year earlier.
What is the company's cash position and guidance outlook?
Cash, cash equivalents, and marketable securities totaled $1,467.9 million as of September 30, 2024. Insmed reiterated full-year 2024 global ARIKAYCE revenue guidance of $340 million to $360 million. The company also expects over 80% of total expenditures to go to clinical and commercial programs.
What are the near-term pipeline milestones?
Insmed remains on track to file the brensocatib NDA for bronchiectasis in Q4 2024 and expects a potential U.S. launch in mid-2025 if priority review is granted. Topline results from the TPIP PAH Phase 2 study are expected in the second half of 2025, and the BiRCh Phase 2b CRSsNP top-line data are expected in the second half of 2025.
04—Continue